Adalimumab: a new alternative biologic agent for chronic plaque psoriasis.

Adalimumab: a new alternative biologic agent for chronic plaque psoriasis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Adalimumab: a new alternative biologic agent for chronic plaque psoriasis. Abstract Text:

Anthony D Ormerod,

Adalimumab: a new alternative biologic agent for chronic plaque psoriasis. Publishing Authors By Initials

AD Ormerod,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Adalimumab: a new alternative biologic agent for chronic plaque psoriasis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The British journal of dermatology

VOLUME: 158

Page Numbers: 435-6

Journal Abbreviation: Br. J. Dermatol.

ISSN: 0007-0963

DAY: 15

MONTH: Mar

YEAR: 2008

Adalimumab: a new alternative biologic agent for chronic plaque psoriasis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 4041

Adalimumab: a new alternative biologic agent for chronic plaque psoriasis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Adalimumab: a new alternative biologic agent for chronic plaque psoriasis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Adalimumab: a new alternative biologic agent for chronic plaque psoriasis.

AFFILIATION: Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen AB25 2ZB, U.K.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Adalimumab: a new alternative biologic agent for chronic plaque psoriasis Related Publications

• A case control study in the Indian subcontinent ethnic population on the effect of return visits and the subsequent development of tuberculosis.
• A case of chordoma presenting in the nasopharynx.
• Abdominal tuberculosis in a district general hospital: a retrospective review of 86 cases.
• Accessible housing: quality, disability and design.
• Acquired coarctation of the aorta--a long-term complication of irradiation.
• Adalimumab: a new alternative biologic agent for chronic plaque psoriasis.
• Bone and joint tuberculosis: CASES IN BLACKBURN BETWEEN 1988 AND 2005.
• British guidelines on the use of biological therapies for psoriasis: a note of clarification on the role of etanercept.
• Challenging Closure of a Patent Foramen Ovale via a Superior Approach.
• Cylindrical-cell carcinoma of the nose.
• Differential diagnosis of shadows in the lung-fields.
• Distribution of epithelial membrane antigen in benign and malignant lesions of the salivary glands.
• Interstitial irradiation of the larynx; a report of eight cases.
• Mammoth interatrial septal aneurysm in the ICE age.
• Patent foramen ovale closure before orthopedic trauma surgery to reduce risk of recurrent systemic fat embolism.
• Percutaneous closure of an iatrogenic atrial septal defect.
• Racial and ethnic harassment and discrimination: in the eye of the beholder?
• Randomized trial of aromatherapy. Successful treatment for alopecia areata.
• Rebound increase in migraines following PFO closure.
• Rebound increase in migraines following PFO closure.
• Recent advances in inflammatory skin diseases.
• Screening coronaries of selected asymptomatic patients with patent foramen ovale: A cautionary note.
• Surgery Insight: percutaneous treatment of prosthetic paravalvular leaks.
• The evidence based treatment of tuberculosis: where and why are we failing?
• The management of cancer of the larynx.
• The mode of action of antrycide.
• Ventricular septal rupture following abciximab infusion.